| Chronic Obstructive Airway Disease

Anoro Ellipta vs Breyna

Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.

Deep comparison between: Anoro Ellipta vs Breyna with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsBreyna has a higher rate of injection site reactions vs Anoro Ellipta based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Breyna but not Anoro Ellipta, including UnitedHealthcare

Category

Anoro Ellipta

Breyna

At A Glance

RouteOral inhalation

FrequencyOnce daily

ClassLAMA/LABA

RouteOral inhalation

FrequencyTwice daily

ClassICS/LABA combination

Indications

Chronic Obstructive Airway Disease

Asthma
Chronic Obstructive Airway Disease
Bronchitis, Chronic
Pulmonary Emphysema

Dosing

Chronic Obstructive Airway Disease 62.5 mcg umeclidinium and 25 mcg vilanterol (1 actuation of ANORO ELLIPTA 62.5/25 mcg) once daily by oral inhalation; do not use more than 1 time every 24 hours.

Asthma (12 years and older) 2 inhalations of 80 mcg/4.5 mcg or 160 mcg/4.5 mcg twice daily by oral inhalation; starting dose based on asthma severity.

Asthma (6 to <12 years) 2 inhalations of 80 mcg/4.5 mcg twice daily by oral inhalation.

Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 2 inhalations of 160 mcg/4.5 mcg twice daily by oral inhalation.

Contraindications

Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to umeclidinium, vilanterol, or any excipient
Use of a long-acting beta2-adrenergic agonist (LABA) without an inhaled corticosteroid (ICS) in patients with asthma

Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
Hypersensitivity to any ingredient in BREYNA

Drug Interactions

1666View drug interactions

1834View drug interactions

Adverse Reactions

Most common (>=1%) Pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, chest pain

Serious Serious asthma-related events (hospitalizations, intubations, death), paradoxical bronchospasm, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention

Postmarketing Palpitations, blurred vision, eye pain, glaucoma, increased intraocular pressure, anaphylaxis, angioedema, urticaria, dysgeusia, tremor, anxiety, dysuria, urinary retention, dysphonia

Most common (>=3%) Nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, oral candidiasis, bronchitis, influenza

Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, pneumonia or lower respiratory tract infections in COPD, immunosuppression, hypercorticism, adrenal suppression

Postmarketing Angina pectoris, tachycardia, atrial fibrillation, cataract, glaucoma, oropharyngeal candidiasis, anaphylactic reaction, hyperglycemia, hypokalemia, tremor, dysphonia, hypotension, hypertension

Pharmacology

Umeclidinium is a long-acting muscarinic antagonist (LAMA) that inhibits M3 receptors in airway smooth muscle to produce bronchodilation; vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.

Budesonide is an inhaled corticosteroid that suppresses inflammation by inhibiting multiple cell types and mediators involved in allergic and non-allergic inflammation; formoterol is a long-acting selective beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing intracellular cyclic AMP.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Anoro Ellipta